Methylene Blue

Methylene blue (methylthioninium chloride) is a thiazine dye and the only FDA-approved treatment for acquired methemoglobinemia, granted to Provayblue in April 2016. Off-label uses include vasoplegic shock, ifosfamide-induced encephalopathy, and intraoperative tissue staining. Repurposing efforts for Alzheimer's disease, conducted under the name LMTM or TRx0237 by TauRx Therapeutics, completed two Phase 3 trials and did not meet primary cognitive endpoints.

The molecule is small, charged, and lipophilic. Molecular weight is 319.85 g/mol. The chemical structure is a tricyclic phenothiazine, which places it in the same structural family as the first-generation antipsychotics and tricyclic antidepressants. At low concentrations it cycles between an oxidized form (methylene blue, blue) and a reduced form (leuco-methylene blue, colorless). That redox cycling is the basis for almost every claimed effect in modern biohacking.

Origins and Medical History

Heinrich Caro at BASF first prepared methylene blue from para-aminodimethylaniline in 1876 for the textile dyeing industry. Paul Ehrlich began using it for staining bacteria and parasites in the 1880s. In 1891, Ehrlich and Paul Guttmann used it as the first synthetic drug against malaria, the first time a synthesized small molecule had been used to treat a human disease. It remained an antimalarial through both World Wars before being displaced by chloroquine.

The methemoglobinemia indication was established by clinical practice over the 20th century, well before modern regulatory approval frameworks existed. The FDA's 2016 ProvayBlue approval formalized what was already a century-old standard of care. The agency granted it as an accelerated approval, with continued approval contingent on verification of clinical benefits in further studies.

The Alzheimer's Question

Modern interest in methylene blue as a neurological drug traces to two threads. One is the work of Claude Wischik at the University of Aberdeen, who proposed in the 1990s that methylene blue could disaggregate tau protein, the molecule that forms neurofibrillary tangles in Alzheimer's brains. The second is the mitochondrial mechanism characterized by Francisco Gonzalez-Lima at the University of Texas at Austin, who has spent two decades showing that low-dose methylene blue improves cellular respiration in animal models.

Wischik's company TauRx Therapeutics took methylene blue into Phase 2 trials under the name Rember, then switched to a purified leuco salt called LMTM (also TRx0237 or hydromethylthionine mesylate) for Phase 3. The first Phase 3 trial (NCT01689233) randomized 891 patients with mild-to-moderate Alzheimer's to 75 mg or 125 mg LMTM twice daily, or 4 mg twice daily as a control intended to maintain blinding via blue urine. Results published in The Lancet in December 2016 showed no benefit on the co-primary endpoints of ADAS-Cog11 and ADCS-ADL. Disease-progression curves at all three doses were nearly identical.

A second Phase 3 trial in mild Alzheimer's (NCT01689246) reached similar conclusions. TauRx has continued to argue, through post-hoc and pharmacokinetic re-analyses, that the 8 mg daily control dose was actually pharmacologically active and that the apparent failure reflects an inadequate placebo. Most independent reviewers have not accepted that framing. The drug now sits in additional Phase 2/3 monotherapy studies under the name HMTM, with no regulatory approval anywhere for any neurological indication.

Regulatory and Legal Status

In the United States, methylene blue is a prescription drug. Provayblue is the FDA-approved injectable form. Oral tablets exist as compounded products in some pharmacies. The biohacking market sells methylene blue as a research chemical, dietary supplement, or "USP grade" oral solution, often through online vendors. None of these formulations have been reviewed by the FDA for cognitive, longevity, or anti-aging claims.

The compound is not on the WADA Prohibited List. Use in sport is not currently restricted, although MAO-A inhibition introduces obvious caution around mood-related performance and antidepressant interactions.

The FDA issued a Drug Safety Communication on October 20, 2011 warning of serious and potentially fatal serotonin syndrome when methylene blue is co-administered with serotonergic psychiatric medications. That warning is now in the official prescribing information for every methylene blue product.

Methylene blue does at least three things in human tissue, and the relative contribution of each to any given claimed effect is unresolved.

The most-discussed mechanism is redox cycling in the mitochondrial electron transport chain (ETC). Low-dose methylene blue (well below 4 mg/kg) accepts electrons from NADH at the level of Complex I and donates them downstream to cytochrome c, effectively bypassing Complex I and Complex III (Rojas et al., 2012). In cell culture, this raises oxygen consumption by up to 70 percent and ATP synthesis by approximately 30 percent. The effect is hormetic. At higher concentrations, the dye instead generates reactive oxygen species and behaves as a pro-oxidant.

The second mechanism is monoamine oxidase A (MAO-A) inhibition. Ramsay and colleagues showed in 2007 that methylene blue is a reversible MAO-A inhibitor with a Ki of roughly 70 nM, placing its inhibitory potency around 100-fold greater than moclobemide at low doses. At plasma concentrations reached by clinical doses of 1 mg/kg IV, MAO-A is essentially fully inhibited and MAO-B is partially inhibited. This is the basis for the serotonin syndrome warning.

The third mechanism is inhibition of nitric oxide synthase (NOS) and guanylate cyclase. By suppressing NO-mediated vasodilation, methylene blue raises systemic vascular resistance. That is why it is used at 1-2 mg/kg IV in refractory vasoplegic shock and septic shock as a rescue agent when catecholamines are insufficient.

A fourth, narrower mechanism is direct interaction with tau protein. Methylene blue oxidizes specific cysteine residues on tau monomers, retaining them in a monomeric conformation and preventing fibril formation. This is the TauRx mechanism, and it is the basis for the LMTM Alzheimer's program. The mechanism is real at the molecular level. Whether it produces clinical benefit at tolerable doses in living patients is the question that the Phase 3 trials answered, and the answer was no.

Pharmacokinetics in humans are described, but inconsistently. Reported half-life ranges from 5.5 hours (Peter et al., 2000) to 14 hours (Walter-Sack et al., 2009) to 24 hours per the manufacturer's package insert. Oral bioavailability is roughly 70 percent. Maximum plasma concentration is reached approximately 30 minutes after intravenous administration. The compound and its leuco metabolites are renally cleared and produce a characteristic blue or blue-green urine.

In clinical settings, methylene blue does three things reliably: it reverses methemoglobinemia within an hour at 1-2 mg/kg IV, it raises blood pressure in vasoplegic shock at similar doses, and it stains tissue blue. Everything else is contested.

For Alzheimer's disease, the LMTM Phase 3 results stand as the definitive negative evidence in mild-to-moderate disease. Subgroup analyses suggesting monotherapy benefit in patients not on donepezil or memantine have been published and re-published, but the original studies were not powered for monotherapy subgroups, and the analyses are post-hoc.

For healthy cognitive performance, the relevant human data is limited. A few small studies have reported short-term improvement in memory tasks and increased fMRI signal in memory-related brain regions following single doses of 0.5 to 4 mg/kg in healthy adults. None have been replicated at scale. No methylene blue product has been studied or approved for cognitive enhancement in healthy individuals.

For the biohacking use case, what users typically describe is increased alertness, mild stimulation, and improved subjective focus at oral doses in the 5-25 mg range. These reports are not from controlled trials. The same low-dose range produces blue urine and bluish staining of mucous membranes, which is harmless but visible.

Methylene blue's only well-characterized human dose-response is for methemoglobinemia: 1 to 2 mg/kg IV, administered over 5 minutes, with a second dose at 30 to 60 minutes if methemoglobin levels remain above 30 percent. For vasoplegic shock the same 1-2 mg/kg IV range is used as a one-time rescue. For ifosfamide-induced encephalopathy, published case series describe 50 mg IV every 4 hours until neurological status returns to baseline.

The Phase 3 Alzheimer's trials used LMTM (a purified leuco form, not direct methylene blue) at 75 mg or 125 mg twice daily. Earlier Phase 2 work with the Rember formulation tested 100 mg three times daily. Both Phase 3 doses failed to outperform 4 mg twice daily on cognitive endpoints.

Off-label biohacking protocols circulating online use 5-30 mg orally per day, often once daily in the morning, sometimes sub-lingually. Some protocols layer in near-infrared (NIR) light exposure, based on the Gonzalez-Lima group's work suggesting that NIR and methylene blue share a final common pathway of cytochrome oxidase stimulation. The published mechanistic basis for the synergy is plausible. Controlled human efficacy data for the stacked protocol is not.

A useful clinical reference point: a 70 kg adult given a single 1 mg/kg dose IV receives 70 mg. Most oral biohacking doses are an order of magnitude lower.

The most-discussed concern is serotonin syndrome. Methylene blue is a potent MAO-A inhibitor at doses as low as 1 mg/kg, and fatal cases have been reported when it is given to patients on SSRIs, SNRIs, MAOIs, tricyclic antidepressants, tramadol, dextromethorphan, or other serotonergic drugs. The original cluster of cases came from intraoperative use during parathyroid surgery in patients on chronic antidepressants. The FDA's 2011 communication advised stopping the serotonergic drug at least 2 weeks (5 weeks for fluoxetine) before non-emergent methylene blue administration.

For acute clinical doses (1-2 mg/kg IV), common adverse effects include nausea, abdominal pain, dizziness, headache, chest pain, dyspnea, and characteristic blue or blue-green discoloration of skin, urine, and feces. The discoloration is harmless and clears in 24 to 48 hours. Diaphoresis, sweating, and confusion can also occur.

Methylene blue is contraindicated in glucose-6-phosphate dehydrogenase (G6PD) deficiency. The drug can precipitate severe hemolytic anemia in G6PD-deficient patients. It is also contraindicated in pregnancy near term: intra-amniotic injection has caused fetal hemolysis, methemoglobinemia, and ileal atresia.

At very high doses, paradoxically, methylene blue itself causes methemoglobinemia rather than treating it. Reported in cases where >7 mg/kg has been given.

Long-term oral use at biohacking doses has not been studied in controlled trials. The MAO-A inhibition is reversible and dose-dependent, but the practical implication is that anyone taking methylene blue chronically should be aware that any new serotonergic medication, including over-the-counter dextromethorphan in cough syrup, can trigger a serotonin reaction.

Methylene blue is most often discussed alongside other mitochondrial-targeting compounds. The pairing with SS-31 (elamipretide) is mechanistically distinct, SS-31 stabilizes cardiolipin on the inner mitochondrial membrane, while methylene blue cycles electrons. The pairing with NAD+ precursors (NMN, NR) is also mechanistically complementary: NAD+ provides the substrate for electron donation, and methylene blue shuttles those electrons past damaged complexes. Neither pairing has been tested in a controlled human trial.

The pairing with near-infrared light (660 nm, 850 nm) is the most-published combination. Both interventions stimulate cytochrome c oxidase. Gonzalez-Lima's group has published rat and small human data on the combination for memory and cerebral blood flow.

The pairing methylene blue should not be in is with any serotonergic agent. This is not a stack risk to be hedged. It is a documented cause of death. Anyone considering methylene blue while on an SSRI, SNRI, MAOI, tricyclic, tramadol, or even high-dose dextromethorphan should consult a prescriber before any dose, regardless of how low or how oral.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.